# Acute Myeloid Leukemia

Acute myeloid leukemia requires rapid confirmation, cytogenetic and molecular risk assessment, treatment-intensity selection, and early transplant planning. Management is increasingly genotype-directed, but supportive care, response assessment, measurable residual disease interpretation, and clinical-trial access remain central to outcomes.

**Clinical question:** How should clinicians confirm, risk-stratify, and select initial therapy for adults with newly diagnosed acute myeloid leukemia?

Updated: 2026-08-21T00:31:41.525549+00:00

## What matters in practice
- Establish AML subtype and therapeutic targets with cytogenetic and molecular testing at diagnosis; contemporary AML classification, prognostic assignment, and treatment selection are genomically driven. [8][18]
- Initial treatment selection should not be based on chronologic age alone; assess physiologic fitness, comorbidity, disease biology, patient goals, and feasibility of intensive therapy. [7][10]
- For patients not eligible for intensive induction, venetoclax-based low-intensity therapy is supported by randomized and prospective clinical evidence, but requires careful management of drug interactions and treatment-related cytopenias. [19][22]
- Measurable residual disease is a major prognostic biomarker and should be interpreted using an assay appropriate to the patient’s leukemia-defining molecular or immunophenotypic features. [8][18]
- Begin allogeneic hematopoietic cell transplantation assessment early for patients whose disease risk, response, and fitness suggest that post-remission transplantation may provide the best curative strategy. [8][18]

## Confirm AML and obtain actionable disease biology promptly

Diagnostic workup must establish lineage, disease-defining genetics, therapeutic targets, and baseline fitness before definitive treatment selection.

AML diagnosis and classification require integrated morphologic, immunophenotypic, cytogenetic, and molecular assessment. The 2022 European LeukemiaNet (ELN) recommendations incorporate contemporary genetic classification into diagnostic reporting, risk stratification, response assessment, and treatment planning. [8][18]

At presentation, obtain peripheral-blood and bone-marrow evaluation sufficient for morphology, multiparameter flow cytometry, conventional cytogenetics, and molecular testing. Molecular results influence prognostic assignment and may identify therapies directed at FLT3 and other actionable genomic lesions; treatment decisions should be updated as delayed molecular results return. [8][18]

Do not allow a single baseline risk label to substitute for longitudinal reassessment. Cytogenetic and molecular findings, remission depth, measurable residual disease (MRD), treatment tolerance, and transplant eligibility each modify the post-remission strategy. [8][18]
- Document a baseline molecular marker when available because it may later support molecular MRD monitoring. [8][18]
- Evaluate for germline predisposition when clinical features or somatic testing raise suspicion; germline confirmation requires DNA from tissue unlikely to contain leukemia cells, such as cultured skin fibroblasts or selected nonhematopoietic sources. [17]
- Coordinate diagnostic testing with a leukemia-focused hematopathology and transplant-capable center when feasible, particularly for adverse-risk disease, ambiguous classification, or suspected inherited predisposition. [8][17][18]

*Diagnostic domains that directly affect initial AML treatment planning. [8][17][18]*

| Domain | Clinical purpose | Actionable implication |
| --- | --- | --- |
| Morphology and marrow assessment | Establish blast burden and provide baseline disease assessment. [8][18] | Supports diagnosis and later response assessment. [8][18] |
| Flow cytometry | Defines immunophenotype and can establish a leukemia-associated profile for MRD assessment. [8][18] | Provides a potential assay for post-treatment disease monitoring. [8][18] |
| Conventional cytogenetics | Identifies chromosomal abnormalities used in disease classification and prognostic assignment. [8][18] | Contributes to ELN risk categorization and post-remission planning. [8][18] |
| Molecular profiling | Identifies recurrent mutations relevant to classification, prognosis, MRD, and targeted treatment. [8][18] | Use results to refine induction, nonintensive therapy, maintenance, and transplant decisions. [8][18] |
| Germline evaluation when indicated | Distinguishes inherited predisposition from somatic leukemia variants. [17] | May affect donor selection, counseling, and surveillance of relatives. [17] |

## Select treatment intensity through disease biology, fitness, and patient goals

The key initial fork is whether intensive remission-induction therapy is appropriate, not whether a patient exceeds an age threshold.

The updated ASH guideline addresses newly diagnosed AML in older adults and emphasizes evidence-based choices among available low-intensity therapies. Older adults are heterogeneous; conventional intensive induction may be inappropriate for some patients, but age alone does not define treatment ineligibility. [7][10]

For a patient considered for intensive therapy, integrate functional status, comorbidity, organ reserve, performance status, adverse disease biology, expected treatment-related toxicity, transplant candidacy, and patient preferences. For a patient not considered eligible for intensive therapy, choose a regimen with an achievable outpatient or inpatient delivery plan, explicit transfusion and infection support, and an early response-assessment strategy. [7][8][10][18]

Genomic risk is clinically consequential because ELN recommendations use genetic findings to categorize prognosis and guide consideration of allogeneic hematopoietic cell transplantation (HCT) in first remission. Risk should be interpreted alongside response quality rather than as an immutable designation. [8][18]
- Discuss treatment intent early: remission induction with potential curative consolidation or HCT, lower-intensity disease control with possible durable remission, or supportive-focused care. [7][10]
- Refer early for HCT evaluation when adverse-risk genetics, suboptimal response, or expected relapse risk may favor transplantation in remission. [8][18]
- Offer clinical-trial enrollment whenever available, particularly for high-risk genomics, secondary AML, relapsed/refractory disease, or patients poorly served by standard options. [19][21]

*Decision framework for initial therapy intensity in newly diagnosed AML. [7][8][10][18]*

| Decision domain | Questions for the treating team | Why it changes management |
| --- | --- | --- |
| Fitness for intensive therapy | Can the patient tolerate prolonged cytopenias, inpatient complications, and intensive induction? [7][10] | Determines whether intensive induction or a lower-intensity approach is more appropriate. [7][10] |
| Disease genetics | Which cytogenetic and molecular lesions establish prognosis or identify a targeted-treatment opportunity? [8][18] | Refines risk, systemic treatment selection, MRD strategy, and HCT planning. [8][18] |
| Response potential | Is deep remission likely and can it be measured with flow or molecular MRD? [8][18] | MRD can modify relapse-risk assessment and post-remission strategy. [8][18] |
| Patient priorities and logistics | What tradeoffs are acceptable regarding hospitalization, toxicity, transfusions, clinic frequency, and curative-intent treatment? [7][10] | Treatment appropriateness depends on informed preference as well as disease and physiologic factors. [7][10] |

## Use regimen-specific evidence and molecular results to guide systemic therapy

AML therapy is regimen-based and should be delivered with protocol-level supportive care and toxicity surveillance.

For patients ineligible for intensive chemotherapy, venetoclax combined with a hypomethylating agent or low-dose cytarabine has prospective clinical-trial support. A phase 3 trial evaluated venetoclax plus low-dose cytarabine in newly diagnosed AML among patients ineligible for intensive chemotherapy, and prospective studies have evaluated venetoclax with azacitidine or decitabine. [19]

Venetoclax administration requires active medication reconciliation because antifungal agents can alter venetoclax elimination through CYP3A-related interactions. Interaction management is especially important because azole antifungal prophylaxis is commonly considered during prolonged neutropenia. [22]

Targeted therapies have expanded AML options, and the ELN treatment recommendations incorporate targeted agents into intensive and nonintensive treatment pathways. Actual regimen selection should be based on the detected lesion, regulatory status, intended treatment backbone, prior therapy, organ function, drug interactions, and local leukemia-program protocols. The supplied evidence does not support specifying U.S. product-label doses in this review. [8][18][19]
- Before venetoclax-based treatment, reconcile CYP3A-modifying drugs and establish an institutional plan for interaction management, tumor lysis surveillance, cytopenia assessment, and antimicrobial prophylaxis. [22]
- Assess marrow response and prolonged cytopenias in relation to treatment cycle timing; do not assume persistent cytopenia represents refractory leukemia without disease assessment. [8][18]
- Use molecular results to determine whether a targeted agent should be incorporated; avoid empiric targeted therapy before confirming the relevant genomic lesion. [8][18]

### What the available evidence supports

The available sources support venetoclax-based low-intensity therapy as an important option for newly diagnosed AML in patients ineligible for intensive chemotherapy, but they do not provide sufficient primary-label detail to reproduce dosing, ramp-up schedules, renal or hepatic adjustments, or exact antifungal dose modifications. Use current FDA prescribing information and institutional protocols for these operational decisions. [19][22]

*Treatment considerations supported by the supplied AML literature. [8][18][19][22]*

| Clinical setting | Evidence-supported consideration | Operational concern |
| --- | --- | --- |
| Newly diagnosed AML eligible for intensive therapy | ELN recommendations incorporate targeted therapies into intensive treatment guidance. [8][18] | Complete cytogenetic and molecular characterization promptly and revise the plan as actionable results return. [8][18] |
| Newly diagnosed AML ineligible for intensive therapy | Venetoclax plus low-dose cytarabine has phase 3 randomized evidence; venetoclax with azacitidine or decitabine has prospective clinical evidence. [19] | Plan for interaction management, cytopenias, infection prevention, and response assessment. [19][22] |
| FLT3-mutated or otherwise molecularly defined AML | Genomic profiling is integral to treatment selection in contemporary AML recommendations. [8][18] | Confirm the lesion and use current regulatory labeling and leukemia-specialist protocols for agent selection. [8][18] |
| Relapsed or refractory AML | Salvage chemotherapy and emerging targeted agents are reviewed as therapeutic approaches. [19] | Reassess disease genetics, transplant feasibility, clinical-trial eligibility, and goals of care. [19][21] |

## Use MRD to refine relapse risk and post-remission planning

Morphologic remission alone is an incomplete measure of treatment effect in AML.

The ELN recommendations identify MRD as a central biomarker in AML response assessment and provide guidance on its role in clinical decision-making. MRD assessment may use molecular methods when a suitable marker is present or multiparameter flow cytometry when an appropriate leukemia-associated immunophenotype can be tracked. [8][18]

Interpret MRD in context. Assay sensitivity, specimen quality, the stability and specificity of the molecular marker, treatment timing, and concordance with morphology and blood-count recovery all affect meaning. A detectable or rising MRD signal generally indicates higher relapse risk, but management should be individualized rather than driven by an isolated result without considering assay and clinical context. [8][18]

Post-remission therapy should be planned before remission is documented. ELN guidance addresses consolidation, maintenance therapy, and timing of allogeneic HCT; the choice depends on genetic risk, remission depth, MRD, prior treatment, patient fitness, donor options, and patient preferences. [8][18]
- Use the same validated MRD approach serially when possible to improve longitudinal interpretability. [8][18]
- Communicate whether MRD is being used for prognostication, treatment selection, transplant planning, or all three; these are related but not interchangeable uses. [8][18]
- Discuss HCT promptly after remission in patients with adverse-risk biology or other features associated with high relapse risk. [8][18]

*Practical interpretation of remission assessments in AML. [8][18]*

| Result | Interpretation | Next clinical action |
| --- | --- | --- |
| Morphologic remission with MRD not detected | Suggests a deeper response than morphology alone, subject to assay performance and timing. [8][18] | Continue risk-adapted post-remission planning; do not disregard baseline genomic risk. [8][18] |
| Morphologic remission with MRD detected | Indicates residual leukemia detectable below morphologic thresholds and may identify greater relapse risk. [8][18] | Review assay validity, repeat-testing plan, consolidation strategy, HCT candidacy, and trial options. [8][18] |
| Persistent morphologic disease | Indicates inadequate response to current therapy. [8][18] | Reassess molecular findings, suitability for salvage therapy, trial enrollment, and transplant strategy if remission can be achieved. [18][19][21] |

## Treat supportive care as part of AML therapy, not an adjunct

Treatment-related cytopenias, infection risk, transfusion dependence, and interaction management can determine whether planned therapy is deliverable.

AML treatment frequently produces prolonged cytopenias and requires a coordinated support plan for blood products, infection evaluation, antimicrobial strategy, metabolic monitoring, and urgent symptom escalation. Low-intensity venetoclax-based regimens also require close surveillance because clinically consequential cytopenias and drug interactions can occur outside the inpatient setting. [19][22]

Medication review should be repeated whenever prophylactic antimicrobials or other new drugs are started, stopped, or changed. CYP3A-related interactions with venetoclax are particularly relevant when antifungal therapy is used. [22]

Care planning should include early goals-of-care discussions alongside disease-directed treatment. For older adults and patients with substantial comorbidity, shared decisions about intensity, expected toxicities, hospitalization, transfusion support, and time at home are integral to appropriate AML management. [7][10]
- Provide patients and caregivers explicit instructions for fever, bleeding, dyspnea, progressive fatigue, medication changes, and missed laboratory visits.
- Coordinate transfusion, antimicrobial, pharmacy, and after-hours pathways before outpatient low-intensity treatment begins.
- Reevaluate treatment intent when toxicity, functional decline, refractory disease, or patient priorities change. [7][10]

*Supportive-care priorities during AML treatment. [7][10][19][22]*

| Priority | Why it matters | Practice implication |
| --- | --- | --- |
| Medication reconciliation | Drug interactions can alter venetoclax elimination. [22] | Review concomitant medications before and throughout venetoclax-containing therapy. [22] |
| Cytopenia surveillance | Both AML and therapy can produce clinically important cytopenias. [19] | Use scheduled blood counts and disease assessment to distinguish treatment effect from persistent leukemia. [8][18][19] |
| Shared decision-making | Fitness and patient preferences affect suitability for intensive versus lower-intensity therapy. [7][10] | Revisit goals and treatment burden at major decision points. [7][10] |

## Common questions

### Should age alone determine whether an adult with AML receives intensive induction therapy?

No. The available guideline-focused sources emphasize that older adults are heterogeneous and that treatment selection should incorporate fitness, comorbidity, disease biology, expected toxicity, and patient preferences rather than age alone. [7][10]

### What testing should be prioritized when AML is suspected or newly diagnosed?

Obtain integrated morphologic, flow-cytometric, cytogenetic, and molecular evaluation because contemporary AML classification, prognostic stratification, targeted-treatment selection, and MRD planning depend on these data. [8][18]

### When is venetoclax-based therapy most relevant in newly diagnosed AML?

Venetoclax combinations are particularly relevant for patients considered ineligible for intensive chemotherapy. Evidence includes a randomized phase 3 trial of venetoclax plus low-dose cytarabine and prospective studies with azacitidine or decitabine. [19]

### Why is antifungal prescribing important during venetoclax therapy?

Antifungal agents may affect venetoclax elimination through CYP3A-related interactions. Medication reconciliation and use of current prescribing information or institutional protocols are necessary whenever interacting agents are considered. [22]

### How should MRD results change AML management?

MRD provides prognostic information beyond morphologic response and can inform post-remission treatment and transplant planning. Interpret it using an assay appropriate to the leukemia, specimen quality, timing, and the patient’s baseline genetic and clinical risk. [8][18]

### When should transplant evaluation begin?

Begin early, especially when adverse-risk genetics, suboptimal response, or high anticipated relapse risk could make allogeneic HCT an important post-remission option. [8][18]

## References
1. Chronic myeloid leukemia - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/276
2. Cell Press — www.cell.com — https://www.cell.com/cell/fulltext/S0092-8674(26)00917-7
3. Global first-in-class drugs approved in 2023–2024 — www.cell.com — https://www.cell.com/the-innovation/fulltext/S2666-6758(25)00004-9
4. Designs of the clinical trials aiming at evaluating ... — www.cell.com — https://www.cell.com/molecular-therapy-family/advances/pdfExtended/S3117-387X(25)00001-1
5. ΔNp73 isoform defines a TP53-mutant-like poor-risk ... — www.cell.com — https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00613-5
6. How I treat AML incorporating the updated classifications and guidelines — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0006497123003671
7. American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2473952925007323
8. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0006497122008874
9. Recently approved therapies in acute myeloid leukemia — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0145212618302078
10. New Clinical Practice Guidelines on AML in Older Adults — journals.lww.com — https://journals.lww.com/oncology-times/fulltext/2020/09050/new_clinical_practice_guidelines_on_aml_in_older.3.aspx
11. Study Details | NCT07700056 | A Study to Evaluate Efficacy ... — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT07700056
12. Application to add azacitidine to WHO Model List of ... — cdn.who.int — https://cdn.who.int/media/docs/default-source/essential-medicines/2021-eml-expert-committee/applications-for-addition-of-new-medicines/a.3_azacitidine_updated.pdf?sfvrsn=f9326d0b_4
13. PubMed - NIH — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov
14. BRCUOnline — learn.asn-online.org — https://learn.asn-online.org/Catalogue/BRCUOnline
15. Volume 148 Issue 4 | Blood | American Society of Hematology — ashpublications.org — https://ashpublications.org/blood/issue/148/4
16. 2025 update on MRD in acute myeloid leukemia: a consensus ... — ashpublications.org — https://ashpublications.org/blood/article/147/11/1147/557333/2025-update-on-MRD-in-acute-myeloid-leukemia-a
17. Diagnosis and management of AML in pediatric patients — ashpublications.org — https://ashpublications.org/blood/article/147/14/1532/547835/Diagnosis-and-management-of-AML-in-pediatric
18. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | Blood | American Society of Hematology — ashpublications.org — https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022
19. Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022 — ascopubs.org — https://ascopubs.org/doi/10.1200/EDBK_349605
20. Study Protocol — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/65/NCT05020665/Prot_000.pdf
21. Study Details | NCT03013998 | Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT03013998
22. Consensus-Based Guidelines for Acute Myeloid Leukemia ... — ascopubs.org — https://ascopubs.org/doi/10.1200/GO.23.00165
23. Management Approach to Acute Myeloid Leukemia ... — ascopubs.org — https://ascopubs.org/doi/10.1200/GO.20.00660
24. HIGHLY CONFIDENTIAL NATIONAL INSTITUTE FOR ... — www.nice.org.uk — https://www.nice.org.uk/guidance/ta425/documents/committee-papers

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.